AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23685525 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquacel Ag
Number of subjects: 24
Study 23685525 — intervention group
Group type: COMPARATOR
Intervention: Silver sulfadiazine
Number of subjects: 24
Study 21242674 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral paricalcitol
Number of subjects: 227
Study 21242674 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 227
Study 21242674 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 227
Study 18940282 — intervention group
Group type: EXPERIMENTAL
Intervention: Proteinuria present (750 patients)
Number of subjects: 5835
Study 18940282 — intervention group
Group type: COMPARATOR
Intervention: No proteinuria (5,085 patients)
Number of subjects: 5835
Study 18940282 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-grade proteinuria
Number of subjects: 5835
Study 18940282 — intervention group
Group type: EXPERIMENTAL
Intervention: High-grade proteinuria
Number of subjects: 5835
Study 16493123 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wine (450 mL daily, 40 grams of alcohol)
Number of subjects: 34
Study 16493123 — intervention group
Group type: COMPARATOR
Intervention: De-alcoholized red wine (450 mL daily)
Number of subjects: 34
Study 12889564 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based educational intervention for IBD patients (8 sessions)
Number of subjects: 49
Study 10859007 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fat, low lactose diet
Number of subjects: 143
Study 10859007 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 143
Study 9453117 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonographic evaluation of lower uterine segment (LUS) thickness
Number of subjects: 123
Study 9453117 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonographic evaluation of LUS thickness with a criterion of 2 mm or less for poor healing
Number of subjects: 123
Study 9453117 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonographic evaluation of LUS thickness in women with poor healing
Number of subjects: 123
Study 9453117 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonographic evaluation of LUS thickness in women with 2 mm LUS thickness
Number of subjects: 123
Study 7938237 — intervention group
Group type: EXPERIMENTAL
Intervention: MSG with 0.5 mM inosine‐5'‐monophosphate (IMP)
Number of subjects: 0
Study 7938237 — intervention group
Group type: EXPERIMENTAL
Intervention: MSG alone
Number of subjects: 0
Study 7938237 — intervention group
Group type: COMPARATOR
Intervention: MSG
Number of subjects: 0
Study 3356357 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate
Number of subjects: 135
Study 3356357 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 135
Study 29473358 — intervention group
Group type: EXPERIMENTAL
Intervention: Guiding-qi acupuncture combined with electroacupuncture (EA)
Number of subjects: 60
Study 29473358 — intervention group
Group type: COMPARATOR
Intervention: Conventional acupuncture (control group)
Number of subjects: 60
Study 27164691 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (1,000 IU orally twice daily for 3 years)
Number of subjects: 337
Study 27164691 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical to vitamin E)
Number of subjects: 337
Study 27164691 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 337
Study 27164691 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 337
Study 25691084 — intervention group
Group type: EXPERIMENTAL
Intervention: True acupuncture
Number of subjects: 14
Study 25691084 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 14
Study 23850555 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic screening for colorectal cancer (CRC) with assumed medium adherence (70%) and contamination (30%)
Number of subjects: 0
Study 23850555 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic screening for colorectal cancer (CRC) with low adherence (50%) and high contamination (50%)
Number of subjects: 0
Study 20572374 — intervention group
Group type: EXPERIMENTAL
Intervention: Chitin‐PAA dressing
Number of subjects: 36
Study 20572374 — intervention group
Group type: COMPARATOR
Intervention: Lipido‐colloid absorbent dressing
Number of subjects: 36
Study 20572374 — intervention group
Group type: COMPARATOR
Intervention: Alginate wound dressing
Number of subjects: 36
Study 18194407 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab combined with radiotherapy
Number of subjects: 0
Study 18194407 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 0
Study 16627836 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulisation with a combination of salbutamol (0.5 mg) and magnesium sulphate (500 mg)
Number of subjects: 100
Study 16627836 — intervention group
Group type: COMPARATOR
Intervention: Nebulisation with salbutamol only (0.5 mg)
Number of subjects: 100
Study 11903240 — intervention group
Group type: EXPERIMENTAL
Intervention: Emulsifying ointments (unguentum emulsificans and dilutions with 30, 50, 70 and 90% aqua purificans)
Number of subjects: 10
Study 11903240 — intervention group
Group type: COMPARATOR
Intervention: Negative control (no treatment)
Number of subjects: 10
Study 9860106 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam 4 mg
Number of subjects: 36
Study 9860106 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam 2 mg
Number of subjects: 36
Study 9860106 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam 2 mg and 4 mg
Number of subjects: 36
Study 9860106 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam (various doses)
Number of subjects: 36
Study 9860106 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 7617137 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRP (4 x 50 micrograms i.v. boluses)
Number of subjects: 0
Study 7617137 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 0
Study 2198165 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline magnesium trisalicylate (CMT) at increasing doses (50-1,500 mg)
Number of subjects: 23
Study 2198165 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline magnesium trisalicylate (CMT)
Number of subjects: 23
Study 2198165 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline magnesium trisalicylate (CMT) at daily 3,000 mg doses for 1 week
Number of subjects: 23
Study 2198165 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 320654 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin pediatric suspension (100 mg ampicillin/kg/24 hours divided in 4 doses)
Number of subjects: 16
Study 320654 — intervention group
Group type: COMPARATOR
Intervention: Pivampicillin base pediatric suspension (64.8 mg/kg/24 hours divided in 4 doses)
Number of subjects: 16
Study 320654 — intervention group
Group type: EXPERIMENTAL
Intervention: Pivampicillin
Number of subjects: 16
Study 320654 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 16
Study 6752082 — intervention group
Group type: EXPERIMENTAL
Intervention: nomifensine
Number of subjects: 27
Study 6752082 — intervention group
Group type: COMPARATOR
Intervention: amitriptyline
Number of subjects: 27
Study 30895713 — intervention group
Group type: EXPERIMENTAL
Intervention: PLGA-coated biphasic calcium phosphate particles (group I)
Number of subjects: 0
Study 30895713 — intervention group
Group type: COMPARATOR
Intervention: Noncoated biphasic calcium phosphate particles (group II)
Number of subjects: 0
Study 29575043 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-day group workshop intervention
Number of subjects: 100
Study 29575043 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 100
Study 26220315 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological support from a professional psychologist during pre-operative visit, hospitalisation, and rehabilitation.
Number of subjects: 200
Study 26220315 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 200
Study 23489888 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual therapy (aspirin 75‐160 mg daily and clopidogrel 300 mg day 1 then 75 mg daily)
Number of subjects: 65
Study 23489888 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy (aspirin 75‐160 mg daily)
Number of subjects: 65
Study 22829901 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully maturated cheese (Parmigiano‐Reggiano; PR)
Number of subjects: 70
Study 22829901 — intervention group
Group type: COMPARATOR
Intervention: Cow's milk (CM)
Number of subjects: 70
Study 22829901 — intervention group
Group type: EXPERIMENTAL
Intervention: Digested PR preparations
Number of subjects: 70
Study 22829901 — intervention group
Group type: EXPERIMENTAL
Intervention: IgE to BLG measured by ISAC
Number of subjects: 70
Study 19323872 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light therapy
Number of subjects: 0
Study 19323872 — intervention group
Group type: COMPARATOR
Intervention: Standard light
Number of subjects: 0
Study 17612824 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Brief Therapeutic Phone Contacts (IBTPC) integrating motivational interviewing and cognitive behavioral therapies
Number of subjects: 43
Study 15197430 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymyxin B-immobilized fiber (PMX-F) treatment (n=15)
Number of subjects: 25
Study 15197430 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (n=10)
Number of subjects: 25
Study 12076241 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone/estrogen replacement therapy (H/ERT)
Number of subjects: 135
Study 12076241 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study 9874467 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa administration for patients receiving cisplatin chemotherapy
Number of subjects: 100
Study 9874467 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa administration for patients receiving noncisplatin chemotherapy
Number of subjects: 100
Study 7622259 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day antibacterial therapy (Penicillin 300 mg/kg for meningococcal and pneumococcal meningitis; Ampicillin 300 mg/kg for Haemophilus influenzae b meningitis)
Number of subjects: 26
Study 7622259 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day antibacterial therapy
Number of subjects: 26
Study 7622259 — intervention group
Group type: COMPARATOR
Intervention: Control group (8 to 15 days of antibacterial therapy)
Number of subjects: 26
Study 7622259 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 26
Study 1978492 — intervention group
Group type: EXPERIMENTAL
Intervention: Remoxipride
Number of subjects: 12
Study 1978492 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 12
Study 318898 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenfluramine
Number of subjects: 20
Study 318898 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 318898 — intervention group
Group type: COMPARATOR
Intervention: Vitamin C absence
Number of subjects: 20
Study 31357534 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional VOO enriched with olive oil PCs (500 mg/kg)
Number of subjects: 22
Study 31357534 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional VOO enriched with olive oil (250 mg/kg) and thyme PCs (250 mg/kg; FVOOT)
Number of subjects: 22
Study 31357534 — intervention group
Group type: COMPARATOR
Intervention: Natural VOO (control intervention; olive oil PCs: 80 mg/kg)
Number of subjects: 22
Study 27620949 — intervention group
Group type: EXPERIMENTAL
Intervention: Malleable factors (peer connections, received friendships)
Number of subjects: 148
Study 27620949 — intervention group
Group type: EXPERIMENTAL
Intervention: Malleable factors (class size, autism symptom severity, peer connections)
Number of subjects: 148
Study 27620949 — intervention group
Group type: EXPERIMENTAL
Intervention: Malleable factors (autism symptom severity, peer connections, received friendships)
Number of subjects: 148
Study 27620949 — intervention group
Group type: EXPERIMENTAL
Intervention: Age (stable factor)
Number of subjects: 148
Study 27620949 — intervention group
Group type: EXPERIMENTAL
Intervention: No stable factors (age, IQ, sex)
Number of subjects: 148
Study 26110375 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone sustained release (NSR) 2.5 mg
Number of subjects: 40
Study 26110375 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone sustained release (NSR) 5 mg
Number of subjects: 40
Study 26110375 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone sustained release (NSR) 10 mg
Number of subjects: 40
Study 26110375 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone sustained release (NSR) 20 mg
Number of subjects: 40
Study 26110375 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 24313686 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT)
Number of subjects: 150
Study 24313686 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense pulsed light (IPL)
Number of subjects: 150
Study 24313686 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue-red light-emitting diode (LED) phototherapy
Number of subjects: 150
Study 23095782 — intervention group
Group type: EXPERIMENTAL
Intervention: Subthalamic nucleus deep brain stimulation (STN-DBS)
Number of subjects: 21
Study 19671333 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (TMZ) therapy, n = 70
Number of subjects: 138
Study 19671333 — intervention group
Group type: COMPARATOR
Intervention: Control group (without TMZ), n = 68
Number of subjects: 138
Study 17901793 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin clavulanate
Number of subjects: 75
Study 17901793 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 17901793 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 75
Study 15140463 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain management intervention (PMI)
Number of subjects: 189
Study 12194936 — intervention group
Group type: EXPERIMENTAL
Intervention: Riboflavin (1.6 mg/day)
Number of subjects: 124
Study 12194936 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 11072399 — intervention group
Group type: EXPERIMENTAL
Intervention: Chart reminders (Condition B)
Number of subjects: 81
Study 11072399 — intervention group
Group type: COMPARATOR
Intervention: Posted memos (Condition A1)
Number of subjects: 81
Study 11072399 — intervention group
Group type: COMPARATOR
Intervention: Posted memos (Condition A2)
Number of subjects: 81
Study 8577657 — intervention group
Group type: COMPARATOR
Intervention: Normal pregnancies
Number of subjects: 0
Study 8577657 — intervention group
Group type: EXPERIMENTAL
Intervention: PECAM, ICAM-1, and ICAM-2 mRNA
Number of subjects: 0
Study 8577657 — intervention group
Group type: EXPERIMENTAL
Intervention: E-Selectin and VCAM-1 mRNA
Number of subjects: 0
Study 2171846 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanadrel sulfate (3 weeks treatment)
Number of subjects: 0
Study 2171846 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3 weeks treatment)
Number of subjects: 0
Study 2171846 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Number of subjects: 0
Study 2171846 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 0
Study 619817 — intervention group
Group type: COMPARATOR
Intervention: Carmustine and fluorouracil (two-drug regimen)
Number of subjects: 38
Study 619817 — intervention group
Group type: EXPERIMENTAL
Intervention: Carmustine, fluorouracil, and spironolactone (three-drug regimen)
Number of subjects: 38
Study 619817 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-drug regimen (carmustine, fluorouracil, spironolactone)
Number of subjects: 38
Study 31703056 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous Transforaminal Endoscopic Discectomy (PTED)
Number of subjects: 250
Study 31703056 — intervention group
Group type: COMPARATOR
Intervention: Microendoscopic Discectomy (MED)
Number of subjects: 250
Study 31703056 — intervention group
Group type: EXPERIMENTAL
Intervention: PTED
Number of subjects: 250
Study 31703056 — intervention group
Group type: COMPARATOR
Intervention: MED
Number of subjects: 250
Study 31703056 — intervention group
Group type: EXPERIMENTAL
Intervention: PTED and MED
Number of subjects: 250
Study 30642911 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel/carboplatin/bevacizumab (PCB)
Number of subjects: 223
Study 26888327 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain-framed message
Number of subjects: 748
Study 26888327 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss-framed message
Number of subjects: 748
Study 26888327 — intervention group
Group type: COMPARATOR
Intervention: Neutral health message (control)
Number of subjects: 748
Study 25388765 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercially‐available herbal dentifrice
Number of subjects: 145
Study 25388765 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% non‐herbal potassium nitrate
Number of subjects: 145
Study 25388765 — intervention group
Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 145
Study 24603308 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-induced acute kidney injury (CI-AKI)
Number of subjects: 2968
Study 23283047 — intervention group
Group type: EXPERIMENTAL
Intervention: Butenafine (BTF)
Number of subjects: 96
Study 23283047 — intervention group
Group type: COMPARATOR
Intervention: Bifonazole (BFZ)
Number of subjects: 96
Study 19853193 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV6/11/16/18 vaccine
Number of subjects: 679
Study 19853193 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 679
Study 17451419 — intervention group
Group type: EXPERIMENTAL
Intervention: Near patient testing for glycated haemoglobin
Number of subjects: 344
Study 17451419 — intervention group
Group type: COMPARATOR
Intervention: Usual laboratory test (Control)
Number of subjects: 344
Study 15206665 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy (15-mg nicotine patch, 4-mg nicotine gum, and/or 10-mg nicotine inhaler)
Number of subjects: 923
Study 15206665 — intervention group
Group type: COMPARATOR
Intervention: Placebo products
Number of subjects: 923
Study 15206665 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 923
Study 15206665 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy
Number of subjects: 923
Study 11409480 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (25 mg, n=9)
Number of subjects: 20
Study 11409480 — intervention group
Group type: COMPARATOR
Intervention: Hyperosmolar glucose (50%, n=9)
Number of subjects: 20
Study 9745800 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive relaxation with stress management training
Number of subjects: 43
Study 9745800 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalic vasomotor feedback with stress management training
Number of subjects: 43
Study 9745800 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol (beta-blocker)
Number of subjects: 43
Study 8201564 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen shields saturated with an antibiotic and a steroid placed in 90 eyes postoperatively
Number of subjects: 183
Study 8201564 — intervention group
Group type: COMPARATOR
Intervention: Control group received the same drugs through a peribulbar/retrobulbar injection in 93 eyes
Number of subjects: 183
Study 3322763 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparation B (Euthyrox)
Number of subjects: 0
Study 3322763 — intervention group
Group type: COMPARATOR
Intervention: Preparation A (L-Thyroxin Henning)
Number of subjects: 0
Study 3322763 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparation C (Levothyroxine, enos)
Number of subjects: 0
Study 30200088 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS on peroneal nerve at 1 Hz
Number of subjects: 24
Study 30200088 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS on peroneal nerve at 5 Hz
Number of subjects: 24
Study 30200088 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS on soleus muscle at 5 Hz
Number of subjects: 24
Study 27054826 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Activation Treatment for Depression (BATD)
Number of subjects: 46
Study 27054826 — intervention group
Group type: COMPARATOR
Intervention: Supportive counseling
Number of subjects: 46
Study 23949727 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mL contrast medium (G30)
Number of subjects: 100
Study 23949727 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mL contrast medium (G40)
Number of subjects: 100
Study 23949727 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mL contrast medium (G50)
Number of subjects: 100
Study 23949727 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mL contrast medium (G60)
Number of subjects: 100
Study 23949727 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 mL contrast medium (G70)
Number of subjects: 100
Study 23007724 — intervention group
Group type: EXPERIMENTAL
Intervention: Voluntary rhythms of each hand
Number of subjects: 0
Study 23007724 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral movements
Number of subjects: 0
Study 23007724 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticomuscular coherence
Number of subjects: 0
Study 23007724 — intervention group
Group type: EXPERIMENTAL
Intervention: Interhemispheric delays
Number of subjects: 0
Study 23007724 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticomuscular delays
Number of subjects: 0
Study 23007724 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-30 Hz corticomuscular coherence during isometric contractions
Number of subjects: 0
Study 20434204 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 5 mg daily (n = 18)
Number of subjects: 36
Study 20434204 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 18)
Number of subjects: 36
Study 18565860 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronedarone 400 mg twice a day
Number of subjects: 627
Study 18565860 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 627
Study 16095415 — intervention group
Group type: EXPERIMENTAL
Intervention: Altitude (AL) condition (P(I)o(2) = 123.1 mm Hg)
Number of subjects: 20